Arcus Biosciences officer plans $83K stock sale
Arcus Biosciences, Inc. (RCUS) is the issuer for a Rule 144 notice filed for the planned sale of its common stock by officer Alexander Azoy.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Arcus Biosciences, Inc. (RCUS) is the issuer for a Rule 144 notice filed for the planned sale of its common stock by officer Alexander Azoy. The filing lists 2,827 shares of common stock, with an aggregate market value of $83,453.04, to be sold through Morgan Stanley Smith Barney LLC, with the shares to be issued upon the exercise of stock options for cash. The notice also references prior 10b5-1 plan sales of 2,562 shares for $66,023.76 on June 1, 2026.
Key Figures
Key Terms
Rule 144 regulatory
10b5-1 regulatory
Exercise of Stock Options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing disclose for Arcus Biosciences (RCUS)?
What prior sales are reported for Alexander Azoy in the past 3 months for RCUS?
AI-generated analysis. How Rhea-AI works. Not financial advice.